Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -16.2%
- Operating Margin Trend +26.27 pp/yr
ALNY
Alnylam Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
6
- 5yr Avg ROE -60.5%
- 5yr Share-Count CAGR 3.3%
Growth Quality
Weight: 35%
B
72
- 5yr Revenue CAGR 44.8%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
D+
41
- 5yr FCF Margin -26.2%
- 5yr FCF/NI Conversion 1.48x
Balance Sheet
Weight: 10%
B+
78
- Net Debt / EBITDA -2.93x
- Interest Coverage (EBIT/Int) 1.99x
- Altman Z-Score 5.98
Stability
Weight: 5%
A+
93
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 7
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.4 of 4 gurus held; 3 added; 1 trimmed; 1 full exit.
- Holders
- 4
- Avg Δ position
- +52.7%
- New buys
- 0
- Full exits
- 1